Peter Lynch · Growth at a reasonable price (GARP)
Is Arbutus Biopharma Corporation (ABUS) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
48/100
Ne correspond pas
2/6 critères validés
Les critères de Peter Lynch, appliqués à ABUS
PEG ≤ 1.0
clé-
EPS CAGR ≥ 15%
clé-
Revenue CAGR ≥ 10%
6.4%
Net margin > 0
84.0%
Comment ABUS se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$682.08M
PER (TTM)
5.1x
ROIC (TTM)
56.72%
Marge brute
99.98%
Autres analyses Peter Lynch
Questions fréquentes
What is ABUS's Peter Lynch fit score?
ABUS scores 48/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own ABUS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ABUS.
How often is this score updated?
ABUS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande ABUS personnellement.
